PARP1 and small cell lung carcinoma: demonstrated that combining the PARP inhibitor (Olaparib) with the Wee1 kinase inhibitor (adavosertib) significantly enhances the effectiveness of olaparib as a single agent in patient-derived xenografts of SCLC (13).